You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Clinical trial defines new standard treatment for advanced Nasopharyngeal Cancer
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointment
Find a Condition or Treatment
Find a Doctor
Menu
MAIN
Back to Home
About Us
Corporate Profile
Newsroom
Visitors Information
Contact Us
Patient Care
Specialties & Services
Your Clinic Visit
Cancer Information & Patient Support
E-Services
Find a Doctor
Research & Innovation
Research Labs
Programmes
Facilities
Our Researchers
Clinical Trials
SingHealth Research
Education & Training
Overview
Professional Development
Division of Cancer Education
Events
SingHealth Academy
Careers
Sponsorship
Scholarships
Giving
Why Give
Get Involved
Your Gift at Work
Be Informed
Make a Gift
Our Campaign
Volunteer
Specialties & Services
Back to Home
Goh Cheng Liang Proton Therapy Centre
Haematology
Medical Oncology
Surgery & Surgical Oncology, SGH and NCCS
Radiation Oncology
Oncologic Imaging
Supportive & Palliative Care
Comprehensive Liver Cancer Clinic
Cancer Genetics Service
Lung Multidisciplinary Clinic
Nursing
NCCS Oncology @ SKH
NCCS Oncology Clinic @ CGH
Department of Psychosocial Oncology
Cancer Education and Information
Your Clinic Visit
Back to Home
Book an Appointment
When seeing a doctor
Pharmacy
Outpatient Pharmacy
Oncology Pharmacy
Search a medication
FAQ
Medicine
Charges & Payment
Financial Aid
Video Consultation
Cancer Information & Patient Support
Back to Home
For Patients
For Caregivers
Publications
Cancer Information Booklets
In Good Health
Inspirational Patient & Caregiver Awards
Patient Stories
E-Services
Back to Home
Make/Change/Cancel Appointment
Request for Medical Report
Health Buddy App
Find a Doctor
Home
to skip to the main content on a page
to skip to the main content on a page
About Us
Back to Home
Corporate Profile
Vision & Mission
NCCS Leadership
Annual Report
Awards
Key Milestones
Whistle-blowing Policy
Newsroom
Press Releases
Check Fake News
Visitors Information
Contact Us
Feedback Form
Patient Care
Back to Home
Specialties & Services
Goh Cheng Liang Proton Therapy Centre
Haematology
Medical Oncology
Surgery & Surgical Oncology, SGH and NCCS
Radiation Oncology
Oncologic Imaging
Supportive & Palliative Care
Comprehensive Liver Cancer Clinic
Cancer Genetics Service
Lung Multidisciplinary Clinic
Nursing
NCCS Oncology @ SKH
NCCS Oncology Clinic @ CGH
Department of Psychosocial Oncology
Cancer Education and Information
Your Clinic Visit
Book an Appointment
When seeing a doctor
Pharmacy
Medicine
Charges & Payment
Financial Aid
Video Consultation
Cancer Information & Patient Support
For Patients
For Caregivers
Publications
Patient Stories
E-Services
Make/Change/Cancel Appointment
Request for Medical Report
Health Buddy App
Find a Doctor
Research & Innovation
Back to Home
Research Labs
Cellular & Molecular Research
Medical Sciences
Clinical Trials & Epidemiological Sciences
NCCS Research Committee & Scientific Advisory Board
Research Divisions Organisation Chart
Programmes
Disease Focus
Research Themes
Joint Breast Cancer Registry
Asia-Pacific Hepatocellular Carcinoma Trials Group
The VICTORY Consortium
Facilities
Overview
Specialised Units
Shared Facilities
Shared Services
Research Contracts and Commercialisation
Our Researchers
Division of Medical Oncology
Division of Surgery & Surgical Oncology, SGH and NCCS
Division of Radiation Oncology
Division of Oncologic Imaging
Division of Supportive and Palliative Care
Cellular and Molecular Research
Division of Medical Sciences
Clinical Trials & Epidemiological Sciences
Research Biennial Book
Clinical Trials
About Clinical Trials
Current Clinical Trials
ECRU
About Clinical Trials & Epidemiological Sciences
Clinical Trials Office
Biostatistics and Epidemiology Unit
SingHealth Research
Education & Training
Back to Home
Overview
Professional Development
Continuing Medical Education
Continuing Nursing Education
Continuing Pharmacist Education
Division of Cancer Education
Undergraduate Education Unit
Postgraduate Education Unit
Nursing & Allied Health Education Unit
Faculty Development & Support Education Unit
Primary Care Oncology Education Unit
Communications, Mentoring, Ethics and Professionalism Education Unit
Medical Humanities Education Unit
Events
SingHealth Academy
Careers
Back to Home
Sponsorship
Career Conversion Programme
Scholarships
Giving
Back to Home
Why Give
About Us
Funding Innovative Research
Preventing Cancer
Advancing Medical Education
Helping Our Patients
Furthering Donor Impact
How Your Gift Helps
Get Involved
Honouring Your Gift
Become a Corporate Donor
Leave Your Legacy
Fundraise for Us
Join a Special Event
Your Gift at Work
Stories of Hope
Researchers in Action
Support for Patients
Our Work in the Community
Training Future Experts
Be Informed
Our Publications
Financial Statements
Make a Gift
Our Campaign
Make More Survivors
Jeans For Genes
Women VS Cancer
BCAM 2023
LCAM 2023
Volunteer
Home
>
Patient Care
>
Clinical trial defines new standard treatment for advanced Nasopharyngeal Cancer
Clinical trial defines new standard treatment for advanced Nasopharyngeal Cancer
Facebook
WhatsApp
Email Us
share
Font Resize
A-
A
A+
Print
By:
Page Content
Nasopharyngeal cancer (NPC) is the eighth most frequent cancer in males in Singapore. The disease predominantly affects the Chinese population, in particular the Cantonese, Teochew and Hokkien dialect groups. About two-thirds of patients are diagnosed with stage three and four nose cancers at the time of presentation.
Concurrent chemo-radiotherapy has been the standard treatment for this subgroup of high-risk patients. This usually entails precise high-dose radiotherapy using intensity modulated radiotherapy (IMRT) techniques, followed by cisplatin (chemotherapy).
Although NPC is extremely sensitive to radiotherapy and treatment is effective in three-quarters of the patients, chances of a relapse are high. "About 20-30 per cent of high-risk patients will relapse in the lungs, liver and bones. Unfortunately, when the disease has spread to the other parts of the body, it is incurable, and accounts for death in 90 per cent of cases," explains Dr Melvin Chua, a senior consultant radiation oncologist at National Cancer Centre Singapore (NCCS).
To improve treatment outcomes for at-risk patients, NCCS and Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou, China, collaborated on a clinical trial. Findings from the trial established a new global standard treatment for high-risk locally advanced NPC.
"We need to optimise our ability to deliver more chemotherapy in combination with chemo-radiotherapy in these patients. Researchers have tried to intensify treatment by applying chemotherapy before chemo-radiotherapy in advanced NPC. We had previously shown that disease control and survival are improved using a triple drug combo, but such treatment is extremely toxic and therefore rarely used," says Dr Melvin Chua, who is also a co-corresponding author of the study.
NCCS and SYSUCC therefore conducted a randomised controlled phase 3 clinical trial to investigate using another chemotherapy regime upfront – a doublet combo of gemcitabine and cisplatin with concurrent chemo-radiotherapy. This was compared to the current standard treatment of chemo-radiotherapy alone, in newly-diagnosed locally advanced NPC patients. Gemcitabine-cisplatin was used given that this regime is the first-line treatment in patients with recurrent NPC that has spread to other parts of the body.
Using the new combination, the multi-centre trial observed one of the highest disease control and survival rates reported to-date, of 85.3 per cent and 94.6 per cent respectively, at 3-years post-treatment. A significant improvement over 76.5 per cent and 90.3 per cent respectively, for those who received the current standard treatment. This improved survival was primarily due to a lower proportion of patients having the cancer recurring in other parts of the body. Treatment was also well tolerated.
Importantly, the more intensive treatment did not increase severe late complications, although there was an increase in low blood counts, nausea and vomiting and liver function abnormalities during treatment.
These results have now established a new standard of care in patients with locally advanced NPC. Induction gemcitabine and cisplatin plus chemo-radiotherapy is a first-line treatment option for these patients.
With the success of this trial, NCCS seeks to foster a deeper collaboration within the multi-centre collaborative trial network to run more novel trials.
1/8/2020 9:19 AM
×
SUBSCRIBE VIA EMAIL
Subscribe to our mailing list to get the updates to your email inbox...
Find a Doctor
Condition & Treatment
Home
Appointment
E-services